RxDoctor Payments Data

Vijay Reddy, MD

Pulmonary Disease · Jonesboro, ARNPI 1164480802

Payments from drug & device makers

$2,103in general payments, 2019–2025

Across 119 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$989
  • Insmed, Inc.$310
  • Pulmonx Corporation$204
  • AstraZeneca$95
  • Merck$79
  • Mylan Specialty L.p.$76
  • plus $349 from 12 others

What the payments were for

  • Food & beverage$1,90190%
  • Education$20210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,103 in reported general payments places this provider in the 30th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$241,052
Medicare patients
702
Services billed
3,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate33$404,337
TezspireTezepelumab-Ekko18$101,201
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$96,702
XolairOmalizumab18$57,695
SymbicortBudesonide/Formoterol Fumarate114$27,800
Breo ElliptaFluticasone/Vilanterol36$16,564
Arnuity ElliptaFluticasone Furoate62$14,081
Fluticasone-SalmeterolFluticasone Propion/Salmeterol84$10,173
Spiriva HandihalerTiotropium Bromide15$7,591
Spiriva RespimatTiotropium Bromide14$7,334
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,069
Incruse ElliptaUmeclidinium Bromide20$7,056
Qvar RedihalerBeclomethasone Dipropionate22$6,704
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$6,382
Albuterol Sulfate HfaAlbuterol Sulfate249$5,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$33$411,67047 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta$989$141,472262 claims
AstraZenecaTezspire, Symbicort$95$129,001132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →